The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: A randomized, multicenter controlled trial

Pancreas

Volumn 37, Issue 4, 2008, Pages 445-448

  Lee, Kyu Taek ^a,d   Lee, Don Haeng ^b   Yoo, Byung Moo ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Inha University School of Medicine   (South Korea)

^c Ajou University School of Medicine   (South Korea)

^d Sungkyunkwan University   (South Korea)

Author keywords

Double blind; Endoscopic retrograde cholangiopancreatography; Hyperamylasemia; Pancreatitis

Indexed keywords

AMYLASE; PLACEBO; SOMATOSTATIN; TRIACYLGLYCEROL LIPASE; PROTECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BALLOON DILATATION; CHOLANGITIS; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; HYPERAMYLASEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSTRUCTIVE JAUNDICE; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; INFUSION; KOREA; MIDDLE AGED; PREMEDICATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERAMYLASEMIA; INFUSIONS, PARENTERAL; KOREA; MALE; MIDDLE AGED; PANCREATITIS; PREMEDICATION; PROTECTIVE AGENTS; SOMATOSTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58149157996     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181733721     Document Type: Article

References (27)

1. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996;335:909-918.
2. Vlavianos P, Chopra K, Mandalia S, et al. Endoscopic balloon dilatation versus endoscopic sphincterotomy for the removal of bile duct stones: a prospective randomised trial. Gut. 2003;52:1165-1169.
3. Disario JA, Freeman ML, Bjorkman DJ, et al. Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones. Gastroenterology. 2004;127:1291-1299.
4. Toda N, Saito K, Wada R, et al. Endoscopic sphincterotomy and papillary balloon dilation for bile duct stones. Hepatogastroenterology. 2005;52: 700-704.
5. Frank CD, Adler DG. Post-ERCP pancreatitis and its prevention. Nat Clin Pract Gastroenterol Hepatol. 2006;3:680-688.
6. Neuhaus H. Therapeutic pancreatic endoscopy. Endoscopy. 2004;36: 8-16.
7. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54:425-434.
8. Cheon YK, Cho KB, Watkins JL, et al. Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc. 2007;65:385-393.
9. Farrell RJ, Mahmud N, Noonan N, et al. Diagnostic and therapeutic ERCP: a large single centre-s experience. Ir J Med Sci. 2001;170: 176-180.
10. Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol. 2006;101:139-147.
11. Sherman S, Lehman GA. ERCP- and endoscopic sphincterotomy-induced pancreatitis. Pancreas. 1991;6:350-367.
12. Dollinger HC, Raptis S, Pfeiffer EF. Effects of somatostatin on exocrine and endocrine pancreatic function stimulated by intestinal hormones in man. Horm Metab Res. 1976;8:74-78.
13. Gullo L, Priori P, Scarpignato C, et al. Effect of somatostatin 14 on pure human pancreatic secretion. Dig Dis Sci. 1987;32:1065-1070.
14. Karalis K, Mastorakos G, Chrousos GP, et al. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest. 1994;93: 2000-2006.
15. Yuan Y, Gong Z, Lou K, et al. Effects and mechanisms of somatostatin analogs on apoptosis of pancreatic acinar cells in acute pancreatitis in mice. J Gastroenterol Hepatol. 2001;16:683-688.
16. Lai KH, Lo GH, Cheng JS, et al. Effect of somatostatin on the sphincter of Oddi in patients with acute non-biliary pancreatitis. Gut. 2001;49: 843-846.
17. Poon RT, Yeung C, Lo CM, et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc. 1999;49:593-598.
18. Arvanitidis D, Anagnostopoulos GK, Giannopoulos D, et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol. 2004;19:278-282.
19. LaFerla G, Gordon S, Archibald M, et al. Hyperamylasaemia and acute pancreatitis following endoscopic retrograde cholangiopancreatography. Pancreas. 1986;1:160-163.
20. Hamilton I, Lintott DJ, Rothwell J, et al. Acute pancreatitis following endoscopic retrograde cholangiopancreatography. Clin Radiol. 1983; 34:543-546.
21. Conn M, Goldenberg A, Concepcion L, et al. The effect of ERCP on circulating pancreatic enzymes and pancreatic protease inhibitors. Am J Gastroenterol. 1991;86:1011-1014.
22. Sternlieb JM, Aronchick CA, Retig JN, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol. 1992;87: 1561-1566.
23. Poon RT, Fan ST. Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results. JOP. 2003;4:33-40.
24. Foster E, Leung J. Pharmacotherapy for the prevention of post-ERCP pancreatitis. Am J Gastroenterol. 2007;102:52-55.
25. Binmoeller KF, Dumas R, Harris AG, et al. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci. 1992; 37:773-777.
26. McCutcheon AD, Race D. Experimental pancreatitis: a possible etiology of post-operative pancreatitis. Ann Surg. 1962;155:523-531.
27. Arvanitakis M, Delhaye M, De Maertelaere V, et al. Computed tomography and magnetic resonance imaging in the assessment of acute pancreatitis. Gastroenterology. 2004;126:715-723.